drugset / Trial / NCT02900378

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

NCT02900378

Phase 3 Completed 621 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary physical activity in HFrEF patients. Physical activity was assessed by the 6 minute walk test, and daily physical activity was continuously measured by means of a wrist-worn accelerometry device from 2 weeks before until 12 weeks after start of study therapy (sacubitril/valsartan or enalapril).

Timeline

Start
2016-12-20
Primary completion
2018-04-11
Completion
2018-04-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 10 mg
Subject LCZ696 Unknown 24 mg
Subject LCZ696 Unknown 26 mg
Subject LCZ696 Unknown 49 mg
Subject LCZ696 Unknown 51 mg
Subject LCZ696 Unknown 97 mg
Subject LCZ696 Unknown 103 mg